CA125联合影像学在肺腺癌化疗疗效评价中的应用研究

Application Research on Evaluation of Prognosis of Lung Adenocarcinoma in CA125 Joint Imaging

目的探讨肿瘤标志物CA125联合影像学在肺腺癌患者化疗疗效评价中的价值。方法选取2010年9月—2013年10月就诊于该院的116例肺腺癌患者病例资料,均经病理学确诊、临床分期为Ⅲ、Ⅳ期且未行手术治疗,统计所有患者化疗前及化疗2周期后血清中CA125的水平。结果化学治疗后,116例患者分为3组:疾病部分缓解的患者组(PR)、疾病稳定的患者组(SD)、疾病进展的患者组(PD)。化疗前3组血清CA125水平差异无统计学意义(F=0.211,P=0.810);化疗2周期后,3组间血清中CA125的水平差异有统计学意义(F=123.09,P=0.00)。结论在肺腺癌患者血清中肿瘤标志物CA125可作为早期疗效评价的参考指标之一,值得在临床上应用推广。

Objective To analyze values of the measurement of serum tumor marker CA125 in the evaluation of chemotherapy efficiency of lung adenocarcinoma.Methods 116 patients with lung adenocarcinoma admitted to our hospital from the February 2010 to October 2013 were selected as the study group and analyzed retrospectively,all patients were confirmed by pathology and the clinical stage were III and IV without surgery.Statistics of CA125 in serum for all patients before chemotherapy and after 2 cycles chemotherapy were measured and compared.Results After chemical therapies,116 patients were divided into three groups： partial response group（PR group）,stable disease group（SD group） and progression disease group（PD group）.There was no statistically significant between the concentrations of tumor marker CA125 in serum of the three groups before chemical therapy（ F=0.211,P=0.810）;after 2 cycles of chemotherapy,there was statistically significant between the concentrations of tumor marker CA125 in serum of the three groups statistically significant（F=123.09,P=0.00）.Conclusion In the serum of lung cancer patients.